



BSW Formulary Update – June 2023

New and Updated Shared Care Agreements/Change in Traffic Light Status

- BSW [Shared Care Agreement \(SCA\) and monitoring guidelines for DMARDs](#) have been updated to include methotrexate, azathioprine and mycophenolate in chronic inflammatory respiratory indications (sarcoidosis and other interstitial lung diseases). Monitoring is as per existing schedule. This is off-label use; additional information is included in our SCA as per British Thoracic Society clinical statement and BSW respiratory team consensus.
- **BSW [Shared Care Agreement \(SCA\) Denosumab \(Prolia®\) for osteoporosis in adults](#)** Section 5 of the SCA (Monitoring requirements) updated to bring CrCl thresholds and monitoring requirements for post injection blood testing in line with [Summary of Product Characteristics](#). Comprehensive advice for recognising and managing hypocalcaemia are also given. Contact details for specialist teams updated.

Minor amendments to Netformulary

- [Sevelamer 2.4g oral powder](#) formulation included in addition to 800mg tablets. (An oversight as the oral powder was already listed as an option in the accompanying SCA). (**AMBER TLS**)
- [Naseptin® cream](#). Information included on recent formulation change. The excipient Arachis oil (peanut oil) has been removed but both the original formulation containing Arachis oil and the revised formulation without Arachis oil will be in circulation in the supply chain until November 2025. **Extra care regarding patient allergy status must be taken when prescribing and dispensing this product during this transition period. (GREEN TLS)**
- [Topical lidocaine 5%](#). Updated to include formulations and indications approved for prescribing (**AMBER TLS**). Note the ointment is 'P' medicine so may be suitable for self-care in some instances.
- [Gepan bladder installation](#). Now included as an option within RUH (**RED TLS**) for interstitial cystitis / bladder pain.
- [Clotrimazole pessaries](#). 100mg and 200mg strength pessaries added to existing 500mg strength entry. (**GREEN TLS**).

What the BSW CCG formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.
- Updating BSW Shared Care Agreements for Subcutaneous methotrexate.



- Reviewing the contraceptive chapter of the BSW formulary.
- Reviewing local emollient prescribing guidance for primary care.
- Working with local community dietitians to update the Oral Nutrition Formulary.
- Working with local specialists to produce guidance on the use of finerenone for CKD in line with NICE [Formulary \(bswformulary.nhs.uk\)](https://www.nice.org.uk/formulary/bswformulary.nhs.uk)
- Working with local neurology specialists to review the Chronic Migraine Pathway and the Biological Treatment Pathway in line with recent and upcoming NICE technology appraisals for drugs used in management of migraine.
- Working with colleagues across RUH/SFT/GWH to update information in our Shared Care Agreement on blood monitoring in females using testosterone as part of HRT regime

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net